Skip to content
Screener

Kailera Therapeutics KLRA Total Equity

Total Equity at other companies

GPA
General Purpose Acquisition Corp.GPAC
-$7.87M+38.7%
Veradermics logo
VeradermicsMANE
$390.64M+744%
BK
BKBK
$44.78B+3.9%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$2.49M-41.5%
Schering-Plough logo
Schering-PloughSGP
$250.11M+463%
Dollar General logo
Dollar GeneralDG
$8.84B+14.8%

Other financials

Income statement

See full
Operating income-$84.7M-314%
Net income-$78.9M-339%
EPS (diluted)-$3,650.00+79.7%

Balance sheet

See full
Cash & equivalents$111.8M+9.9%
Total debt$10.5M—
Total assets$624.8M—

Cash flow

See full
Operating cash flow-$68.3M-275%

Valuation

See full
Market cap$2.44B-15.8%
Enterprise value$2.34B—

Returns & leverage

See full
Debt / equity-0×—
Current ratio9.7×—

Where this comes from

Reported directly by Kailera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026. Open the filing →

Filed
May 26, 2026, 4:29 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-239417

FAQ

What is Kailera Therapeutics's total equity?
Kailera Therapeutics (KLRA) reported total equity of -$432.09M in Q1 2026.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Kailera Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude